Replimune Group, Inc. (REPL)
NASDAQ
Key stats Fiscal year 2026
Income statement
- Net income
- -313,940,000
- Operating income
- -319,919,000
- Earnings per share
- -3.38
- R&D expense
- 221,184,000
Growth and profitability
- Return on equity
- -188.94
- Return on assets
- -94.45
Balance sheet
- Total assets
- 332,388,000
- Total liabilities
- 166,228,000
- Shareholders' equity
- 166,160,000
- Cash and equivalents
- 209,024,000
- Debt
- 83,308,000
- Net debt
- -125,716,000
- Current ratio
- 4.79
- Debt to equity
- 0.50
Cash flow and ratios
- Operating cash flow
- -280,344,000
- Free cash flow
- -284,567,000
Shareholder returns
- Shares outstanding
- 94,800,404
- Book value per share
- 1.75
Company information
- Headquarters
- Woburn, MA
- Exchange
- NASDAQ
- Fiscal year end
- 03-31
- Industry (SEC)
- Biological Products, (no Diagnostic Substances)
Fiscal year end: · Source: SEC EDGAR
Replimune Group, Inc. trades on NASDAQ under the ticker symbol REPL. This page brings together its price chart, company profile, key financial figures and technical indicators.